Physician profile
Shuja Rasool
NPI 1588841340
$3,664.83
in general payments reported to CMS, 2019-2025
23 companies · $128 in 2025
The $128 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $499 · 2020: $543 · 2021: $1,521 · 2022: $454 · 2023: $277 · 2024: $243 · 2025: $128.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $648.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $648.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,082.58 | 2021-2025 | Micra, Linq II |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $525.66 | 2019-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $436.60 | 2019-2025 | |
| Amgen INC. | $347.91 | 2019-2022 | |
| Boston Scientific Corporation | $244.16 | 2020-2024 | Eluvia |
| Baxter Healthcare | $164.20 | 2023-2024 | Hillrom - Cardiac Ambulatory Monitor, Hillrom - Carnation Ambulatory Monitor |
| Cardiovascular Systems INC. | $144.80 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $111.59 | 2020-2022 | |
| Abbott Laboratories | $99.63 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $92.15 | 2019-2022 | |
| Pfizer INC. | $72.56 | 2021-2023 | |
| Sanofi-Aventis U.S. LLC | $66.23 | 2019-2021 | |
| Astellas Pharma US INC | $59.60 | 2019-2020 | |
| Philips North America LLC | $41.29 | 2020-2022 | |
| Innovation Technologies INC | $28.51 | 2025 | Irrisept |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $26.14 | 2019-2020 | |
| Scpharmaceuticals INC. | $21.26 | 2024 | |
| Bardy Diagnostics, INC. | $20.00 | 2021 | |
| Merck Sharp & Dohme LLC | $18.67 | 2021 | |
| Janssen Pharmaceuticals, INC | $16.55 | 2021 | |
| Terumo Medical Corporation | $15.20 | 2025 | Angio-Seal |
| Novo Nordisk INC | $15.06 | 2023 | Rybelsus, Ozempic |
| E.R. Squibb & Sons, L.L.C. | $14.48 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shuja Rasool listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.